Abstract: Early detection (localized stage) of colon cancer is associated with a five-year survival rate of 91%. Only 39% of colon cancers, however, are diagnosed at that early stage. Early and accurate diagnosis, therefore, constitutes a critical need and a decisive factor in the clinical treatment of colon cancer and its success. In this study, using supervised linear discriminant analysis, we have developed three diagnostic biomarker models that-based on global micro-RNA expression analysis of colonic tissue collected during surgery-can discriminate with a perfect accuracy between subjects with colon cancer (stages II-IV) and normal healthy subjects. We developed our three diagnostic biomarker models with 57 subjects [40 with colon cancer (stages II-IV) and 17 normal], and we validated them with 39 unknown (new and different) subjects [28 with colon cancer (stages II-IV) and 11 normal]. For all three diagnostic models, both the overall sensitivity and specificity were 100%. The nine most significant micro-RNAs identified, which comprise the input variables to the three linear discriminant functions, are associated with genes that regulate oncogenesis, and they play a paramount role in the development of colon cancer, as evidenced in the tumor tissue itself. This could have a significant impact in the fight against this disease, in that it may lead to the development of an early serum or blood diagnostic test based on the detection of those nine key micro-RNAs.
Introduction
Colorectal cancer is the third most common type of cancer for both males and females. In 2010, there were an estimated 102,900 new cases of colon and 39,670 cases of rectal cancer, and an estimated 51,370 deaths from colorectal cancer occurred. 1, 2 The five-year survival rate for those patients who are diagnosed at an early stage (localized stage-stage I or II) is 91%; however, only 39% of colorectal cancer patients are diagnosed at an early stage. 1 If the colorectal cancer has spread to adjacent organs or lymph nodes, the five-year survival drops to 70%, and if it has spread to distant organs, the five-year survival is 11%. 1 It follows, therefore, that early and accurate diagnostic tests would have a significant impact in the fight against this disease by saving thousands of lives every year. Furthermore, if an early and accurate diagnostic test were based on serum or blood, then it would have additional significant advantages: it would be considerably less invasive and expensive than colonoscopy, the current standard diagnostic procedure for colon cancer (CCA).
In this study, we analyzed the global micro-RNA (miRNA) expression data of colonic tumor and healthy tissue obtained during surgery from 96 subjects [68 with CCA (stages II-IV) and 28 normal]. We developed three different and independent diagnostic biomarker models using 57 subjects [40 with CCA (stages II-IV) and 17 normal], and we validated all three of them with 39 unknown subjects [28 with CCA (stages II-IV) and 11 normal] that were new and different from those 57 subjects used in the development of the models. Our three diagnostic biomarker models were able to identify with a perfect accuracy (overall sensitivity: 100.00% and overall specificity: 100.00%) all 68 subjects with CCA and all 28 normal subjects.
Each of our three diagnostic biomarker models is a linear discriminant function of a number of miRNAs. Altogether, nine miRNAs constitute the input variables to all three diagnostic biomarker models, and they are deemed highly significant in the discrimination between healthy normal tissue and tumor tissue, as well as, therefore, in the development of colon cancer.
Materials and Methods

Data acquisition
We used the normalized miRNA data for 68 subjects with CCA (stages II-IV) (labeled 'pMMR') and for 28 normal subjects by Sarver et al 3 posted at the GEO (Gene Expression Omnibus) of the NCBI (National Center for Biotechnology Information) [ID: GSE18392].
Discovery and validation studies
Of the total 96 subjects, we randomly selected 57 of them [40 with CCA (stages II-IV) and 17 normal (NRM)] for the development and training of the diagnostic biomarker models. The remaining 39 subjects [28 with CCA (stages II-IV) and 11 NRM] constituted the unknown subjects with which all diagnostic biomarker models were tested. This validation method provided us with the means to test our diagnostic biomarker models with 39 new and real unknowns that were different from the subjects used for-and, therefore, completely extraneous to-the development and training of the models. The proportions of the stages (II-IV) in the total set of 68 CCA subjects were maintained in both the discovery and validation subsets of CCA subjects.
Statistical methods
In order to reduce the dimensionality of the data and zero in on those variables (miRNAs) that are most significant in the process that differentiates between normal healthy tissue and CCA tissue, we applied our bioinformatic methods that we have developed, presented, and explained in a great detail in our previous studies. [4] [5] [6] [7] Briefly, we performed ROC curve analysis on the entire data matrix, i.e., on all variables (735 miRNAs × 96 subjects) in order to assess the discriminating capability of all variables with respect to our two groups, namely, CCA and NRM. In the final round, we selected only those variables with an AUC $ 0.97. Twelve variables (miRNAs) fulfilled this criterion, and they constituted the final pool of the most significant variables. We should point out that our method used in this study constitutes a novel linear discriminant analysis method, i.e., one that is carefully supervised by ROC curve analysis.
generation of linear discriminant functions
From the aforementioned 12 most significant variables, 9 became the input variables to the three linear discriminant functions (D 1 , D 2 , and D 3 ), which we were able to generate in the discovery study {57 subjects [40 with CCA (stages II-IV) and 17 NRM]}. Those three different and independent linear discriminant functions are the final diagnostic biomarker models. The D 1 is a function of the following 4 of the 9 aforementioned significant variables (miRNAs):
The letter 'T' preceding the name of a miRNA indicates that that miRNA variable was transformed in order to meet normality, equality of variance, and/or equality of covariance requirements.
The D 2 is a function of the following 3 of the 9 aforementioned significant variables (mi RNAs):
The D 3 is a function of the following 4 of the 9 aforementioned significant variables (miRNAs): 2 , and D 3 scores of the 57 subjects used in the discovery study are all zero. In order to avoid having to deal with negative scores, especially in the case of the graphs, we centered all three discriminant functions at +20.
Computer programs
Computer programs were written using MATLAB R2011b by The MathWorks, Inc., Natick, MA, USA.
Results
Discovery study
As was mentioned earlier, from the total number of 96 subjects [68 with CCA (stages II-IV) and 28 NRM] used in this study, we randomly selected 57 subjects [40 with CCA (stages II-IV) and 17 NRM] for the development and training of the three diagnostic biomarker models (D 1 , D 2 , and D 3 ); and we will henceforward refer to those 57 subjects as the 57 original subjects. After the development of the three diagnostic biomarker models, we assessed their diagnostic accuracy using the aforementioned 57 original subjects, which were employed for their development. This constitutes an important first step in the assessment of a diagnostic test.
The cut-off score of the D 1 diagnostic biomarker model, as well as those of the other two models, was determined by taking into account the results of the following two analyses: (1) calculation of the optimal point on the ROC curve based on the 57 scores of the 57 original subjects used in the discovery study [optimal point is defined as the point with the highest sensitivity and the lowest false positive rate (1-specificity)] and (2) calculation of the 99.99% confidence intervals for the mean D 1 scores of the two groups (CCA and NRM) and their respective standard deviations. Based on that, the cut-off score of the D 1 model was determined to be 21.800. If a subject has a D 1 score less than 21.800, then that subject is classified as a CCA; otherwise ($21.800), that subject is classified as an NRM. As can be seen from Figure 1 , the D 1 model correctly identified all (40/40) CCA subjects and all (17/17) NRM subjects. Since our target group is the CCA group, and since our reference group is the NRM group, it follows that, for the discovery study, the D 1 model exhibited a sensitivity = 40/40 = 1.000 and a specificity = 17/17 = 1.000. Figure 1 and Table 2A show all pertinent statistical results of the D 1 diagnostic biomarker model in connection with the discovery study in great detail. The cut-off score of the D 2 diagnostic biomarker model was determined to be 21.235. If a subject has a D 2 score less than 21.235, then that subject is classified as a CCA; otherwise ($21.235), that subject is classified as an NRM. As can be seen from Figure 1 , the D 2 model correctly identified all (40/40) CCA subjects and all (17/17) NRM subjects. Therefore, for the discovery study, the D 2 model exhibited a sensitivity = 40/40 = 1.000 and a specificity = 17/17 = 1.000. Figure 1 and Table 2A show all pertinent statistical results of the D 2 diagnostic biomarker model in connection with the discovery study in great detail.
Regarding the D 3 diagnostic biomarker model, the cut-off score was determined to be 21.382. If a subject has a D 3 score less than 21.382, then that subject is classified as a CCA; otherwise ($21.382), that subject is classified as an NRM. As can be seen from Figure 2 , the D 3 model correctly identified all (40/40) CCA subjects and all (17/17) NRM subjects. Therefore, for the discovery study, the D 3 model exhibited a sensitivity = 40/40 = 1.000 and a specificity = 17/17 = 1.000. Figure 2 and Table 2A show all pertinent statistical results of the D 3 diagnostic biomarker model in connection with the discovery study in great detail. Figure 3 shows the 3D scatter plot of the D 1 vs. D 2 vs. D 3 scores of all 57 original subjects, providing, thus, a visual depiction of the diagnostic accuracy of all three models with respect to the discovery study. As can be seen, the two groups are segregated into two distinct and completely separate clusters: the CCA group (purple spheres) is at the front and lower level, whereas the NRM group (green spheres) is at the back and higher level. It can also be seen that there were no misclassifications by any of the three diagnostic models.
Validation study
As was mentioned earlier, from the total number of 96 subjects [68 with CCA (stages II-IV) and 28 NRM] used in this study, we had randomly segregated 39 subjects [28 with CCA (stages II-IV) and 11 NRM] for the sole and express purpose of testing our three diagnostic biomarker models. Those 39 unknown subjects were completely extraneous to all three models, that is to say they were new and different from the original 57 subjects used for the development of the three models, and they had never before been encountered by any of the three models. This constitutes the most important test in the assessment of a diagnostic test. The significance level was set at α = 0.001 (two-tailed), and the probability of significance for the D 1 was P = 3.05 × 10 −25 (independent t-Test with T-value = 18.4664), whereas the probability of significance for the D 2 was P = 3.01 × 10 −26 (independent t-Test with T-value = 19.3834). Both the D 1 and the D 2 are parametrically distributed with respect to both groups. 18.1475 ± 1.2818 24.5298 ± 1.6149
notes: (A) The ROC AUC value, the T value and probability of significance (P) of the independent t-Test, the 99.99% confidence interval for the mean score of the CCA group and that of the NrM group, along with their respective standard deviations, of the D 1 , D 2 , and D 3 diagnostic biomarker models in the Discovery Study are shown. (B) The ROC AUC value, the T value and probability of significance (P) of the independent t-Test, and the mean score of the CCA group and that of the NrM group, along with their respective standard deviations, of the D 1 , D 2 , and D 3 diagnostic biomarker models in the Validation Study are shown. As can be seen, all six of those group mean scores, as observed in the validation study with the 39 unknown subjects, fall within the 99.99% confidence intervals of the respective group mean scores as predicted in the discovery study (A). 18 .0010 (top of the purple bar) and the standard deviation (whiskers above or below the top of the purple bar) was 0.9684. The mean D 3 score of the 17 NrM subjects was 24.7016 (top of the green bar) and the standard deviation (whiskers above or below the top of the green bar) was 1.0730. The significance level was set at α = 0.001 (two-tailed), and the probability of significance for the D 3 was P = 4.96 × 10 −30 (independent t-Test with T-value = 23.1476). The D 3 is parametrically distributed with respect to both groups. Table 2B , all three diagnostic biomarker models correctly diagnosed all of the 39 unknown subjects. More specifically, all 28 unknown CCA subjects had D 1 , D 2 , and D 3 scores that were less than the respective cut-off scores (21.800, 21.235, 21.382); whereas all 11 unknown NRM subjects had D 1 , D 2 , and D 3 scores that were greater than the respective aforementioned cut-off scores. Therefore, in connection with the validation study, both the sensitivity and the specificity of all three diagnostic biomarker models were 1.000. Figure 6 shows the 3D scatter plot of the D 1 vs. D 2 vs. D 3 scores of all 39 unknown subjects, providing, thus, a visual depiction of the diagnostic accuracy of all three models with respect to the validation study. As can be seen, the 39 unknown subjects are segregated into two distinct and completely separate clusters: the CCA group (purple spheres) is at the front and lower level, whereas the NRM group (green spheres) is at the back and higher level. It can also be seen that there were no misclassifications by any of the three diagnostic models. . As can be seen, there are two distinct, separate clusters: the purple one (CCA group) is at the front and at a lower level, whereas the green one (NrM group) is at the back and at a higher level. It can also be seen that there were no misclassifications.
As can be seen from Figures 4 and 5 and
the two groups (CCA and NRM) of the 39 unknown subjects. As can be seen, all six of those group mean scores, as observed in the validation study with the 39 unknown subjects, fall within the 99.99% confidence intervals of the respective group mean scores as predicted in the discovery study (Table 2A) .
Overall diagnostic biomarker model performance
If we combined the discovery study results with those of the validation study, then the overall performance of our three diagnostic biomarker models would be as follows. All three of them (D 1 , D 2 , and D 3 ) exhibited an overall sensitivity = 1.000 (68/68 CCA subjects) and an overall specificity = 1.000 (28/28 NRM subjects).
On the top 12 most significant miRNAs
In connection with the aforementioned 12 most significant miRNAs identified in our study, we conducted an Ingenuity Pathway Analysis (IPA) search. We sought to ascertain information about those 12 miRNAs pertaining to their known interactions with genes; their known interactions with drugs, chemicals, and/or hormones; and their known associations with various types of cancer as derived from the findings of scientific, peer-reviewed studies. The IPA search results are listed in Table 1 , along with the direction of the statistically significant differential expression (over-expression or under-expression) of those 12 miRNAs in the CCA group relative to that of the NRM group. As can be seen from Table 1 , nearly all of those 12 miRNAs are known to interact with genes, such as RASA1, TP53, CDK6, BCL10, EGR1, and RB1-genes that are involved in the regulation of oncogenesis. Numerous miRNAs have been observed to be differentially expressed in various types of cancer as compared with the normal healthy state. More specifically, miR-183 and miR-135b have been observed to be over-expressed in colon cancer cells as compared to healthy tissue cells, 8, 9 and that agrees with our results (Table 1) . Also in connection with colon cancer, miR-182* and miR-224 have been observed to be over-expressed, whereas miR-30a-3p and miR-137 have been observed to be under-expressed; 8 those observations are also in agreement with our findings ( Table 1 ). In connection with colon cancer cell lines, miR-182 and miR-147 have been observed to be over-expressed and under-expressed, respectively; 8 and that also accords with the results of our analysis ( Table 1 ). In the cases of hypopharyngeal squamous cell carcinoma and gastric cancer, miR-378 has been observed to be under-expressed, 9, 10 which is in agreement with our findings. In the cases of prostate cancer and lung cancer, miR-30a-5p has been observed to be under-expressed, 11, 12 and that is also in agreement with our findings.
The original study by Sarver et al 3 was an observational study. Using the criteria of P value and fold change, the authors reported over forty miRNAs that were determined to be differentially expressed between the subjects with colon cancer and the normal subjects. We should point out here that Sarver et al 3 did not develop any diagnostic models (tests), much less validate them with unknown subjects that were new and different from the original subjects and report the performance results of such diagnostic models (tests).
Discussion
Having employed 57 subjects [40 with CCA (stages II-IV) and 17 NRM], we were able to generate three different and independent linear discriminant functions, i.e. three different and independent diagnostic tests, that, based on the global miRNA analysis of tissue, can diagnose with perfect accuracy colon cancer. Following validation with 39 unknown (new and different) subjects [28 with CCA (stages II-IV) and 11 NRM], our three diagnostic tests (D 1 , D 2 , and D 3 ) exhibited an overall sensitivity = 1.000 (68/68 CCA subjects) and an overall specificity = 1.000 (28/28 NRM subjects). This robust performance should be further tested using a wider pool of subjects in terms of demographics, family history, and syndromic associations.
The clinical significance of our study is as follows. We were able to develop and independently validate three different and independent diagnostic tests that, based on the global miRNA analysis of tumor and healthy tissue, can discriminate with a perfect accuracy between subjects with colon cancer and normal subjects. The nine most significant miRNAs identified, which comprise the input variables to our three diagnostic tests, play, therefore, a key role in the development of colon cancer, as evidenced by the tissue analysis. If an accurate and reliable detection and quantification of those nine key miRNAs were possible in the circulation (plasma or serum), then that would lead to early, accurate, and far less invasive diagnostic tests for colon cancer. Since early detection . As can be seen, there are two distinct, separate clusters: the purple one (CCA group) is at the front and at a lower level, whereas the green one (NrM group) is at the back and at a higher level. It can also be seen that there were no misclassifications.
of colon cancer is associated with 91% survival, 1 the results of our study may have a significant impact in the fight against this disease by contributing to the saving of thousands of lives of patients with colon cancer each year.
Detection of miRNAs in the circulation, be it in circulating tumor cells 13 or in exosomes, 14, 15 has been demonstrated by numerous studies over the last several years. Circulating miRNAs have also been detected in connection with various types of cancer, such as breast cancer, 15 prostate cancer, 16 liver cancer, 17 esophageal cancer, 18 etc. Therefore, identifying and quantifying accurately and reliably, either in serum or in plasma, the aforementioned nine miRNAs that play a key role in the development of colon cancer constitutes the ultimate goal of this study.
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